JP2024544698A - 高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態 - Google Patents

高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態 Download PDF

Info

Publication number
JP2024544698A
JP2024544698A JP2024534196A JP2024534196A JP2024544698A JP 2024544698 A JP2024544698 A JP 2024544698A JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024544698 A JP2024544698 A JP 2024544698A
Authority
JP
Japan
Prior art keywords
salt
hyperglycemia
treatment
diabetes
tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544698A5 (https=
JPWO2023105035A5 (https=
Inventor
ペルクマン，ベンジャミン
Original Assignee
アトロジー アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトロジー アーベー filed Critical アトロジー アーベー
Publication of JP2024544698A publication Critical patent/JP2024544698A/ja
Publication of JP2024544698A5 publication Critical patent/JP2024544698A5/ja
Publication of JPWO2023105035A5 publication Critical patent/JPWO2023105035A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024534196A 2021-12-09 2022-12-09 高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態 Pending JP2024544698A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2117828.0 2021-12-09
GB2117828.0A GB2613616A (en) 2021-12-09 2021-12-09 New formulations
PCT/EP2022/085133 WO2023105035A1 (en) 2021-12-09 2022-12-09 Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2

Publications (3)

Publication Number Publication Date
JP2024544698A true JP2024544698A (ja) 2024-12-03
JP2024544698A5 JP2024544698A5 (https=) 2025-12-05
JPWO2023105035A5 JPWO2023105035A5 (https=) 2025-12-05

Family

ID=80079964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534196A Pending JP2024544698A (ja) 2021-12-09 2022-12-09 高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態

Country Status (11)

Country Link
US (1) US20250042856A1 (https=)
EP (1) EP4444699A1 (https=)
JP (1) JP2024544698A (https=)
KR (1) KR20240116482A (https=)
CN (1) CN118525004A (https=)
AU (1) AU2022405700A1 (https=)
CA (1) CA3241501A1 (https=)
GB (1) GB2613616A (https=)
IL (1) IL313292A (https=)
MX (1) MX2024006960A (https=)
WO (1) WO2023105035A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4651867A1 (en) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202303229D0 (en) * 2023-03-06 2023-04-19 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2020198466A1 (en) * 2019-03-27 2020-10-01 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Also Published As

Publication number Publication date
KR20240116482A (ko) 2024-07-29
EP4444699A1 (en) 2024-10-16
MX2024006960A (es) 2024-06-24
AU2022405700A1 (en) 2024-06-20
GB202117828D0 (en) 2022-01-26
CN118525004A (zh) 2024-08-20
US20250042856A1 (en) 2025-02-06
GB2613616A (en) 2023-06-14
CA3241501A1 (en) 2023-06-15
WO2023105035A1 (en) 2023-06-15
IL313292A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US12280023B2 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
EP3681872B1 (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US20250042856A1 (en) Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2
TWI846843B (zh) 適用於治療高血糖症的雜環基(苯基)甲醇化合物
US12378216B2 (en) Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia
US11793774B2 (en) Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
US20240010620A1 (en) Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereof
TW202444695A (zh) 用於治療高血糖症及特徵在於高血糖症之病症的環己基或雜環烷基β－羥基烷基胺
WO2025186320A1 (en) Combinations of beta 2-adrenergic receptor agonists and sglt2 inhibitors for use in treating hyperglycaemia or a disorder characterized by hyperglycaemia
EP4676481A1 (en) Combination of beta-2-adrenergic receptor agonists and glp-1 receptor agonists for use in treating hyperglycaemia
TW202438055A (zh) 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類
BR112020005045B1 (pt) Composição farmacêutica compreendendo betahidroxietilaminas de fluorofenila, seu uso e kit de partes para o tratamento de hiperglicemia ou um distúrbio tendo hiperglicemia como um sintoma
HK40033371A (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
HK40033371B (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251127